ASSOCIATION OF PLASMA PROCALCITONIN WITH VARIOUS COMPONENTS OF METABOLIC SYNDROME AND INSULIN RESISTANCE

Ali Jassim Turki; Prof. Dr. Jamal Ahmed Abdul Barry; Dr. Hussain Ali Nwayyir

Ali Jassim Turki Department of Biochemistry, Faculty of Medicine, University of Basrah
Prof. Dr. Jamal Ahmed Abdul Barry Department of Biochemistry, Faculty of Medicine, University of Basrah
Dr. Hussain Ali Nwayyir Department of Medicine, Faculty of Medicine, University of Basrah Department of Biochemistry, Faculty of Medicine, University of Basrah

Keywords: Procalcitonin, Metabolic Syndrome, Insulin Resistance, obesity

Abstract

The study investigates the relationship between insulin resistance and metabolic syndrome and plasma procalcitonin, a biomarker of inflammation. The metabolic syndrome, a collection of disorders that includes dyslipidemia, hypertension, hyperglycemia, and abdominal obesity, raises the risk of type 2 diabetes and cardiovascular illnesses. One of the main elements of metabolic syndrome is insulin resistance. Adipocyte dysfunction and persistent low-grade inflammation may be markers for elevated levels of plasma procalcitonin, which have been linked to higher measures of obesity, metabolic syndrome components, and a higher chance of developing insulin resistance and metabolic syndrome.

Objectives:

To investigate the correlation between plasma Procalcitonin (PCT) and metabolic syndrome components such as abdominal obesity, dyslipidemia, hypertension, hyperglycemia, and insulin resistance, in comparison to healthy individuals.

Result: In this study, 80 healthy participants served as controls, while 120 patients with metabolic syndrome (MetS) were included. Procalcitonin (PCT) levels were found to be considerably higher on average in MetS patients as compared to controls in the study. In particular, the average PCT level for MetS patients was 0.122±0.168 ng/ml, compared to 0.086±0.0047 ng/ml for controls. Given that there was a statistically significant difference between the two groups, PCT may have application as a MetS biomarker.

Subsequent investigation demonstrated a strong relationship between PCT and HOMA-IR-measured insulin resistance. The two had a 0.187 Pearson correlation coefficient, and the p-value was less than 0.05. Furthermore, a number of Metabolic Syndrome components, including BMI, waist circumference, triglycerides, VLDL, hypertension, and fasting blood glucose, were found to significantly correlate with PCT. Nevertheless, no meaningful association between PCT and LDL-C was discovered. Conclusion: The study found that the mean level of procalcitonin (PCT) was significantly higher in patients with metabolic syndrome (MetS) compared to controls.

References

1. Huang PL. A comprehensive definition for metabolic syndrome. Disease models & mechanisms. 2009 Apr 30;2(5-6):231-7.
2. Ajlan SK. Metabolic syndrome among obese versus non- obese persons in Basrah. Al- Kindy College Medical Journal. 2012; 8: 112-120.
3. Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. Published 2022 Jan 12. doi:10.3390/ijms23020786.
4. Yang R, Hu Y, Lee CH, Liu Y, Diaz-Canestro C, Fong CH, Lin H, Cheng KK, Pravelil AP, Song E, Lam KS. PM20D1 is a circulating biomarker closely associated with obesity, insulin resistance and metabolic syndrome. European Journal of Endocrinology. 2022 Feb 1;186(2):151-61.
5. Ajlan SK, Abdulkader AA, Mijbil AY , The impact of metabolic syndrome in type 2 diabetic patients. The Medical journal of Basrah University 2012; 30: 85-90.
6. Khodarahmi M, Siri G, Erahimzadeh F, Farhangi MA, Shanehbandi D. Dietary glycemic index and glycemic load mediate the effect of CARTPT rs2239670 gene polymorphism on metabolic syndrome and metabolic risk factors among adults with obesity. BMC Endocrine Disorders. 2022 Nov 21;22(1):288.
7. Yousif HY, Ajlan SK. Insulin Resistance and Residual ß-Cell Function Among Persons with Impaired Fasting Glycaemia. Azerbaijan Medical Journal (AMJ) 2022; 62: 3255-3265.
8. Mansour AA. The prevalence of metabolic syndrome among patients with type 2 diabetes mellitus in Basrah. Middle East Journal Family Medicine. 2007 May 1; 5:20-.
9. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6. doi:10.1097/01.hco.0000200416.65370.a0.
10. RAJWAL N, SINGH J, NEUPANE N. STUDY OF METABOLIC SYNDROME IN INDIAN POPULATION WITH COMPARISON OF TWO DEFINITIONS. Asian J Pharm Clin Res. 2022;15(9):47-53.
11. Ahmadi M, Keshavarz SA, Abbasi B. Effects of alpha lipoic acid supplementation on serum lipid profile in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial. ARYA atherosclerosis. 2022 Jul;18(4):1.
12. M S, Ds DR, N A, Krishnan M. Atherogenic index of plasma, lipid accumulation and visceral adiposity in metabolic syndrome patients. Bioinformation. 2022;18(11):1109-1113. Published 2022 Nov 30. doi:10.6026/973206300181109.
13. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. 2020;16(1):12-18. doi:10.2174/1573402115666190415161813.
14. Vyas A, Keswani P, Sharma S, Khandelwal M, Pilaniya M, Sharma R. A Study of Association of Plasma Procalcitonin with Various Components of Metabolic Syndrome and Insulin Resistance. J Assoc Physicians India. 2022;70(4):11-12.
15. Bajpai D, Pednekar S, Pandey D, Moulick ND, Humane D, Bedmutha K. Association of Plasma Procalcitonin with Various Components of Metabolic Syndrome and Insulin Resistance in Urban Indian Population: A Novel Biomarker. The Journal of the Association of Physicians of India. 2018 Dec 1;66(12):35-8.
16. Abbasi A, Corpeleijn E, Postmus D, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011;54(9):2463-2465. doi:10.1007/s00125-011-2216-3